Eris Lifesciences has successfully completed the acquisition of the probiotics business from Velbiom Probiotics Private Limited. This marks the closure of a transaction initially announced on 20 March 2026. The acquisition aligns with Eris Lifesciences‘ strategic objective to enhance its product offerings in the probiotics segment. The company had previously communicated its intention to acquire Velbiom’s probiotics business, and the finalisation of this deal underscores its commitment to expanding its footprint in the health and wellness sector. This acquisition is expected to bolster Eris Lifesciences’ position in the probiotics market, providing a broader range of products to its customers.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).